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the initiation of malaria infection. One-way ANOV A method is 
used for analysing the data. 
Figure 5.2 IFNy concentrations of control and treated malarial mice. Effect 149 
ofrmIL-18BP, AmIL-18 and rmIL-18 on the production ofIFNy 
in malarial mice. Mice infected with P. berghei (2 x 107 PRBC, 
i.v.) received rmIL-18BP or AmIL-18 or rmIL-18 (l!Jg/mouse, 
i.v.) on day 0-4 after infection, and the concentration ofIFNy in 
serum taken on day 1, 3 and 5 were measured by using ELISA. 
Each column represents the mean of S.E.M. of six mice. C+NS 
= Control + Normal saline; M+NS = Malaria 1:" Normal saline; 
M+rmIL-18BP = Malaria + recombinant mouse IL-18 binding 
protein; M+AmIL-18 = Malaria + Anti-mouse IL-18 
monoclonal antibody; M+rmIL-18 = Malaria + recombinant 
mouse IL-18. *,"¢ and ~ denote the significant differences 
(P<0.05) between the M+NS group and M + (rmIL-18BP or 
AmIL-18 or rmIL-18) groups on day 1, 3 & 5 respectively after 
the initiation of malaria infection. One-way ANOVA method is 
used for analysing the data. 
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Figure 5.3 IL-l a concentrations of control and treated malarial mice. Effect 152 
of rmIL-18BP, AmIL-18 and rmIL-18 on the production of IL-
Ia in malarial mice. Mice infected with P. berghei (2 x 107 
PRBC, i.v.) received rmIL-18BP or AmIL-18 or rmIL-18 
(l/-tg!mouse, i.v.) on day 0-4 after infection, and the 
concentration of IL-l a in serum taken on day 1, 3 and 5 were 
measured by using ELISA. Data are presented as mean of 
S.E.M. of six mice. C+NS = Control + Normal saline; M+NS = 
Malaria + Normal saline; M+rmIL-18BP = Malaria + 
recombinant mouse IL-18 binding protein; M+AmIL-18 = 
Malaria + Anti-mouse IL-18 monoclonal antibody; M+rmIL-18 
= Malaria + recombinant mouse IL-18. '" and ~ denote the 
significant differences (P<0.05) between the M+NS group and 
M + (rmIL-18BP or AmIL-18 or rmIL-18) groups on day 1, 3 & 
5 respectively after the initiation of malaria infection. One-way 
ANOV A method is used for analysing the data. 
Figure 5.4 IL-6 concentrations of control and treated malarial mice. Effect 154 
ofrmIL-18BP, AmIL-18 and rmIL-18 on the production ofIL-6 
in malarial mice. Mice infected with P. berghei (2 x 107 PRBC, 
i.v.) receivedrmIL-18BP or AmIL-18 or rmIL-18 (l/-tg!mouse, 
i.v.) on day 0-4 after infection, and the concentration of IL-6 in 
the serum of control and treated malarial mice taken on day 1, 3 
and 5 was measured during infection by using ELISA. Data are 
presented as mean of S.E.M. of six mice. C+NS = Control + 
Normal saline; M+NS = Malaria + Normal saline; M+rmIL-
18BP = Malaria + recombinant mouse IL-18 binding protein; 
M+AmIL-18 = Malaria + Anti-mouse IL-18 monoclonal 
antibody; M+rmIL-18 = Malaria + recombinant mouse IL-18. '" 
and ~ denote the significant differences (P<.0.05) between the 
M+NS group and M + (rmIL-18BP or AmIL-18 or rmIL-18) 
groups on day 1, 3 & 5 respectively after the initiation of 
malaria infection. One-way ANOV A method is used for 
analysing the data. 
Figure 5.5 5 IL-I0 concentrations of control and treate,d malarial mice. 157 
Effect of rmIL-18BP, AmIL-18 and rmIL-18 on the production 
of IL-I0 in malarial mice. Mice infected with P. berghei (2 x 
107 PRBC, i.v.) received rmIL-18BP or AmIL-18 or rmIL-18 
(l/-tg/mollse, i.v.) on day 0-4 after infection, and the 
concentration of IL-IO in the serum of control and treated 
malarial mice iaken on day 1, 3 and 5 were measured by using 
ELISA. Data are presented as mean of S.E.M. of six mice. 
C+NS = Control + Normal saline; M+NS = Malaria + Normal 
saline; M+rmIL-18BP = Malaria + recombinant mouse IL-18 
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binding protein; M+AmIL-18 = Malaria + Anti-mouse IL-18 
monoclonal antibody; M+nnIL-18 = Malaria + recombinant 
mouse IL-18. * and <l> denote the significant differences 
(P<O.05) between the M+NS group and M + (nnIL-18BP or 
AmIL-18 or nnIL-18) groups on day 1, 3 & 5 respectively after 
the initiation of malaria infection. One-way ANOVA method is 
used for analysing the data. 
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MENYELIDIKI PENGLIBATAN INTERLEUKIN-18 DAN KESAN 
PENGUBAHSUAIANNYA TERHADAP PELEPASAN SITOKIN-SITOKIN 
UTAMA SEMASA JANGKIT AN MALARIA DALAM MEN CIT 
ABSTRAK 
IL-18 merupakan sitokin pro-inflamasi poten yang memainkan pelbagai peranan 
dalarn tindakbalas imunisasi dan aktiviti inflarnasi dalarn banyak penyakit, tetapi 
penglibatannya dalarn mendasari patogenesis malaria masih belum terhurai sepenuhnya. 
DaUun kajian ini, peranan dan penglibatan IL-18 semasajangkitan malaria diselidiki dan 
penilaian awal telah dijalankan tentang kesan modulasi laluannya ke atas perkembangan 
jangkitan dan sitokin utarna yang dirembeskan semasa jangkitan. Jangkitan Plasmodium 
berghei ANKA pada mencit ICR digunakan sebaga( model malaria sepanjang kaji~ ini. 
Haiwan diinokulasi secara intravena dengan 2 X 107 sel darah merah berparasit (PRBC) 
yang diperolehi daripada mencit pendenna yang dijangkiti parasit. Haiwan kawalan 
menerima isipadu dan pencairan (0.2 mL, i.v.) sel darah merah mencit nonnal (RBC) 
yang sarna. Keputusan menunjukkan bahawa mencit malaria memperlihatkan perubahan 
tingkah laku sakit pada hari keempat selepas inokulasi, iaitu ketika paras parasitemia ~ 
60% dan terus meningkat sehingga parasitaemia beredar mencapai sekitar 80%. Mencit 
yang dijangkiti tewas kepada hiperparasitemia 5-6 hari selepas infeksi. Mencit ICR juga 
menunjukkan penurunan suhu badan dan berat badan yang signifikan ketika parasitemia 
puncak. Kepekatan IL-18 dalam plasma yang ditentukan melalui kaedah ELISA, 
menunjukkan peningkatan yang signifikan sepanjang jangkitan dan satu hubungan 
korelasi yang positif dengan perkembangan parasitemia telah diperhatikan. Oleh kerana 
jangkitan malaria menyebabkan ketidakfungsian pelbagai organ, tisu-tisu dari organ-
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organ utama yang diketahui terpengaruh semasa jangkitan termasuk limfa, hati, otak, 
paru-paru dan ginjal telah diperiksa bagi pengekspresan IL-18 menggunakan kaedah 
SDS-PAGE dan analisa Western blot. Kajian mendapati bahawa IL-18 diekspreskan 
pada intensiti yang berbeza dalam limfa, hati, otak dan paru-paru. Tiada IL-18 dikesan 
dalam ginjal mencit semasa jangkitan. Pengeluaran IL-18 semasa jangkitan malaria 
dimodulasi melalui rawatan dengan rmIL-18BP, AmIL-18 dan rmIL-18. Pemberian ' 
rmIL-18BP dan AmIL-18 menghalang perkembangan parasitemia pada tahap awal 
infeksi. Perencatan signifikan terhadap perkembangan parasit berlaku pada hari pertama 
hingga ketiga selepas rawatan. Selepas rawatan, berat badan dan suhu badan mencit 
malaria menurun pada hari keempat hingga keenam daripada nilai awal eksperimen. 
Pemberian rmIL-18 menyebabkan paras parasitemia meningkat lebih pantas diikuti 
dengan penu~an berat badan dan suhu badan.· Mencit- malaria yang diberi rmIL-18 
didapati mati lebih awal. Hasil kajian ini juga menunjukkan bahawa perencatan terhadap 
IL-18 melalui pemberian rmIL-18BP dan AmIL-18 telah menurunkan pelepasan paras 
IFNy, TNFa, IL-6 dan IL-l tetapi meningkatkan paras IL-lO secara signifikan. 
Sebaliknya, peningkatan pengeluaran IL-18 meningkatkan paras IFNy, TNFa, IL-6 dan 
IL-l dan menurunkan paras IL-IO secara signifikan dalam serum semasa jangkitan 
malaria. Kesimpulannya, hasil kajian ini mencadangkan bahawa IL-18 terlibat semasa 
jangkitan malaria dan memainkan peranan penting sebagai perantara terhadap ketenatan 
penyakit tersebut. Modulasi laluannya menghasilkan kesan yang signifikan ke atas 
rangkaian sitokin semasa jangkitan di mana ini mungkin mencadangkan. bahawa 
modulasi terhadap penghasilan IL-18 semasa jangkitan boleh menjadi satu konsep 
terapeutik yang berpotensi bagi terapi malaria 
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INVESTIGATING INTERLEUKIN-18 INVOLVEMENT AND 
ITS MODULATORY EFFECTS ON MAJOR CYTOKINES RELEASE 
DURING MALARIA INFECTION IN MICE 
ABSTRACT 
IL-18 is a potent pro inflammatory cytokine that plays multiple roles in immune' 
responses and inflammatory activities in many disease conditions, but its involvement in 
the underlying pathogenesis of malaria has not been fully elucidated. In this study, the 
role and involvement of IL-18 during malaria infection was investigated and the impact 
of its pathway modulation on the course of the infection and the major cytokines 
released during the infection was preliminary evaluated. Plasmodium berghei ANKA 
infection in ICR mice were used as malaria model througho~t the study. The animals 
were inoculated intravenously with 2 x 107 parasitized red blood cells (PRBCs) obtained 
from a donor mouse infected with the parasite. The control animals received an 
equivalent volume and dilution (0.2 mL, i.v.) of normal mouse RBC. Results 
demonstrated that the malarial mice showed sick behavioral. changes on day 4 after 
inoculation when the levels of parasitaemia were ~ 60% and then continued to increase 
until circulating parasitaemia reached around 80%. The infected mice succumbed to 
hyperparasitaemia 5-6 days after infection. ICR mice also showed significant decrease in 
body temperature and body weight during the peak parasitaemia. IL-18 concentrations in 
the plasma determined by means of ELISA, showed significant elevation thrOl~ghout the 
infection and a positive correlation with parasitaemia development. Since malaria 
infection causes multi organ dysfunction, tissues from major organs known to be 
affected during malaria infection which include the spleen, liver, brain, lungs and kidney 
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were examined for IL-18 expression using SDS-PAGE and Western blot analysis. The 
study revealed that IL-18 was expressed in different intensity in the spleen, liver, brain 
and lungs. No IL-18 was detected in the kidney of mice during the infection. IL-18 
production during malaria infection was modulated by treatment with rrnIL-18BP, 
ArnIL-18 and rrnIL-18. Treatment with rrnIL-18BP and ArnIL-18 inhibited the 
parasitaemia development at early phase of infection. Significant inhibition on parasites' 
development occurred on day 1 until day 3 after treatment. Body weight as well as body 
temperature of malarial mice decreased on day 4 until day 6 from thei~ initial values 
after the treatment. rrnIL-18 treatment caused the parasitaemia levels to increase rapidly 
followed by a decrease in body weight and body temperature. Earlier mortality was also 
observed in the malarial mice treated with rrnIL-18. Results also showed that inhibition 
ofIL-18 by treatment with rrnIL-18BP and ArnIL-18 significantly reduced the release of 
pro-inflammatory cytokines IFNy, TNFa, IL-6 and IL-la levels and on the other hand 
increased the level of anti-inflammatory cytokine IL-IO significantly. In contrast, 
augmentation of IL-18 production significantly increased the levels of the pro-
inflammatory cytokines and reduced the level of the anti-inflammatory cytokine in the 
serum during the infection. In conclusion, the results from this study suggest that IL-18 
is involved during malaria infection and it may well playa crucial role in mediating the 
severity of the disease. Its pathway modulation produced a significant impact on the 
cytokine network during the infection which may suggest that modulating IL-18 
production during malaria infection could be a promising therapeutic concept for malaria 
therapy. 
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CHAPTER 1 
GENERAL INTRODUCTION 
1.1 The problem of malaria 
1.1.1 Endemic problem 
Malaria is a major public health problem that causes severe morbidity and 
mortality in the tropical and sub tropical countries such as Africa, South America, ' 
Eastern Europe and Asia. The disease potentially affects about half of the world's 
population and more than 3 billion people are at risk of being infected. It is estimated 
that 250 million cases led to nearly 1 million deaths from malaria annually (WHO, 
2008). Young children under 5 years old and pregnant women, especially 
primigravidae are the highest risk groups for malaria in the endemic areas (WHO, 
1999). Up to 10,000 pregnant women (Guyatt and Snow, 2001) and 200,000 
newborns (Steketee et al., 2001) died as a consequence of malaria during pregnancy 
annually. 
Malaria is endemic in 101 countries and is caused by a parasite, Plasmodium. 
Plasmodium Jalciparum and P. vivax are co-occurring in 61 countries. P. Jalciparum 
occurs in 28 countries, mainly in tropical Africa, and accounts as the major source of 
malaria in Africa which causes 83% of the total case of malaria. Whereas, P. vivax 
occurs in other 12 countries such as North Africa, Latin America and Western Asia 
and accounts as the major source of malaria in Australasia which causes 74% of the 
total case of malaria in the region (Schlagenhauf-Lawlor, 2001). As the parasite -
P. vivax could be distributed widely and recorded to have about 70-80 million cases 
annually (Mendis et a!., 2001). With the current increase of global traveling, malaria 
has become a threat to human health worldwide. 
1.1.2 Drug resistant 
There has been many research aimed to control malaria, for instance the 
discovery of chloroquine and other antimalarials as well as the development of 
insecticides to eliminate the vector. Unfortunately, the efficacy of antimalarial drugs 
and insecticides in controlling malaria has yet to be optimised. In addition, the 
parasite has developed resistance to previous found malarial drugs such as 
chloroquine, the spread of multi drug resistant strains to newer classes of antimalarial 
drugs (Newton and White, 1999), The increased resistance of the vector to 
insecticides are related to lack of infrastructure in endemic countries (Pinzon-Charry 
et al., 2006; Asahi, et al., 2005). 
1.1.3 Socio economic problem 
Many of the world's poorest people live in areas with high rates of malaria. 
Thus malaria is also called the disease of the poor and associated with social and 
economic hardships (WHO, 2002). The economic impact includes (a) households, 
(b) health systems, and (c) national economies. At the household level, malaria 
imposes both direct and indirect costs. Direct costs include time lost from work and 
medical treatment costs (including transportation and medical care). Indirect costs 
include loss of work efficiency and time and work reallocation within the household. 
For children in particular, indirect costs also include, nutritional deficiencies, 
cognitive and educational disabilities, and physical retardation (Hutubessy et al., 
2001). Costs to health care include treatment and medication costs. In most 
economies, households pay a small amount for treatment and medication, with the 
rest of the cost borne by the health system. These direct and indirect impacts above 
can collectively impede economic development and growth. It is estimated to cause a 
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decline in economic growth in the range of 0.25% to 1.3% of per capita gross 
national product (GNP) growth in tropical countries (Guerin et aZ., 2002; Sachs and 
Malaney, 2002). 
1.2 Malaria parasite 
Malaria is a parasitic infectious disease which is predominantly intracellular 
parasites found in blood and tissues. The disease is caused by protozoa of the genus· 
Plasmodium belongs to family Plasmodiidae, phylum Apicomplexa (Menard, 2000). 
One hundred and twenty species of Plasmodium are found in the blood of mammals, 
reptiles and birds. Nonetheless, Plasmodium and Laverania are the subgenera that 
contribute to humans malaria. There are four foremost known species of malaria 
parasites that infect humans: P. falciparum, P. vivax, P. malariae and P. ovale which 
are exclusively transmitted by female mosquito of the Anopheles genus (Warrel and 
Gilles, 2002; Malaguarnera and Musumeci, 2002a; Ramasamy, 1998). Particularly, 
P. falciparum is the most virulent form of malaria and the major cause of mortality 
(Warrell and Gilles, 2002). 
The common type of mixed infections is P. falciparum with P. vivax and is 
found in the subtropical area. While in tropical Africa, the more frequent mix is 
between P. falciparum and P. malariae or P. ovale. Infections by more than two 
species at a time are rare occasions and could be differentiated via microscopic 
examination of blood smears. Clinical observation has shown that the different 
species of malaria parasites cause different symptoms (Warrell and Gilles, 2002). 
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1.3 The life cycles of malaria parasite 
There are two kinds of reproduction cycles of malaria parasite, which are 
sexual and asexual. The sexual reproduction (sporogony) occurs in insect vector -
mosquito, whereas asexual reproduction occurs in the vertebrate host (pre-
erythrocytic schizogony and erythrocytic schizogony) (Warrell and Gilles, 2002). 
1.3.1 The life cycles of malaria parasite in human 
During a blood meal, a malaria-infected female Anopheles mosquito 
inoculates sporozoites into the human host (into the peripheral circulation) by 
depositing saliva on the skin. The saliva contains an anticoagulant, a topical 
anaesthetic and a form of the sporozoite resident (Davidson and Gowda, 2001). Then 
the sporozoite travel through the bloodstream and invades hepatocytes (liver 
parenchymal cells) within 1 hour of inoculation. The sporozoite surface protein 
contains a domain that is homologous to thrombospondin and thus has a very high 
affinity to human hepatocyte receptors, serum proteins thrombospondin and 
properdin, and thereby infects the hepatocytes (Boutin et ai., 2005). Following liver 
invasion, the parasites begin to develop and multiply asexually over a period of about 
one week into an exoerythrocytic schizont containing approximately 10,000-30,000 
merozoites (Warrell and Gilles, 2002). In P. vivax and P. ovale, dormant hypnozoite 
forms can persist in the liver and cause relapses by inv~ding the bloodstream in 
weeks, months or even years later. Contrariwise, there is no dormant fonn of 
P. Jalciparum. The rupture of infected liver cells releases merozoites into the 
bloodstream, that will invade the red blood cells (RBes) to undergo erythrocytic 
schizogony, thereby initiating the erythrocytic cycle merozoite which develops into a 
ring trophozoite. This occurs within a parasitophorous vacuole in the RBC (Boutin et 
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at., 2005; Ramasamy, 1998). Ring trophozoites synthesize proteases to degrade 
haemoglobin into amino acids. These and other nutrients obtained from the host ' 
enable the parasite to grow within 15-18 hours into mature trophozoites (Ramasamy, 
1998), and finally into a schizont, which gives rise to approximately 16 new 
merozoites (Boutin et at., 2005; Ramasamy, 1998). The parasite dramatically alters 
the physiological and biochemical processes of its host's RBC (Boutin et at., 2005) 
and adorns its surface with parasite-encoded molecules that further affect the RBCs ' 
mobility and trafficking within the body (Chowdhury and Bagasra, 2007). Following 
rupture of the infected erythrocytes, merozoites are released and infect new 
erythrocytes. To complete the life cycle in human host, some merozoites develop 
into male and female gametocytes within the RBCs. They will enter the mosquito's 
gut after it bites an infected human. Male and female gametes emerge from the 
infected RBCs in a process referred to as exflagellation. The gametes fertilized in the 
gut giving rise to ookinetes that burrow into the gut wall. The ookinete traverses the 
midgut epithelium to develop into an oocyst and result in the production of infected 
sporozoites which migrate to the salivary gland of the mosquito to continue the 
infection cycle (Okie, 2005; Boutin et at., 2005). Figure 1.1 demonstrates the malaria 
parasite life cycle in the human and mosquito host (Chowdhury and Bagasra, 2007). 
In P. Jatciparum infection, merozoites invade the red blood cells and 
reinitiate an erythrocytic cycle as of once in three days and caused malignant tertian 
malaria. P. vivax and P. ovate have also a 48 hours development period that causes 
benign tertian and ovale tertian malaria respectively. The other human malaria 
parasite, P malariae, has a longer cycle that lasts 72 hours. It is responsible for 
benign qumian malaria, in which patients present symptoms every four days. 
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Figure 1;1: The life'cycle of malaria parasite, adapted from Chowdhury and Bagasra(2007). 
Parasites of any of these four species can develop simultaneously in the same patient 
(Warrell and Gilles, 2002). 
The ability of the organism to invade erythrocytes that cause parasitaemia 
depends on the species of Plasmodia. Merozoites from species of P. vivax and P. 
ovale could only invade reticulocytes (immature erythrocytes) at the erythrocytic 
stage of the life cycle, which serves to limit the magnitude of parasitaemia in these 
types of malaria (Warrell, 2002; Sinden and Gilles, 2002; Powell and Grima, 2002). 
P. malariae can invade mature erythrocyte and the progress is slow in both human 
and mosquito and therefore leads to lower degree of parasitaemia (Sinden and Gilles, 
2002; 'ivTarrell, 2002). P. falciparum has the ability to invade all age 'of RBCs and 
therefore causes a very high level of parasitaemia (higher than in the other species) 
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that rapidly direct to severe or most frequently fatal cases of malaria (Lallo et ai., 
2007; Warrell, 2002; Heddini, 2002). 
1.4 Malaria symptoms 
1.4.1 Fever 
Fever is the most common presenting symptoms of malaria infection (Warrell 
and Gilles, 2002) and it is directly related to the release of blood merozoite upon the' 
break up of the parasitized red blood cells (PRBCs) while the schizogony ends with 
relatively synchronous at the initial stages of infection (Ramasamy, ~ 998; Lopez-
Antufiano and Schmunis, 1990). Fever due to tertian malaria occurs every 48 hours 
in P. Jaiciparum, P. vivax and P. ovaie infection and quartan malaria occurs every 72 
hours in P. maiariae (Lopez-Antufiano and Schmunis, 1990). 
In P. Jaiciparum infection, fever is accompanied by nausea, headache and 
chills (Ramasamy, 1998). At the time of schizont rupture, the lipid glycosyl 
phosphatidyl inositol (GPI) and merozoite surface protein 1 (MSP-l) are released, 
which are toxic and cause intermediate production of pyrogenic cytokines, such as 
interleukines (IL-l, IL-6, IL-8), interferon (IFNy) and tumour necrosis factor-a 
(TNFa) that are released by activated macrophage (Warrell et aI., 2002; Leon, 2002). 
The height and magnitude of fever is a sum of the interaction of pyrogenic cytokines 
and endogenous anti pyretics (Leon, 2002). Indeed, TNFa has been implicated as the 
major cause of malarial fever (Warrell et ai., 2002). 
In a non-immune individual infected with vivax malarial, the typical symptom 
is chill, which may last for one hour. During this period, body temperature rises 
sharply, reaching to -41 DC within the first two hours after the onset of the chill, then 
temperature begin to fall and accompanied by profuse sweating (Karunaweera et aI., 
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1992). Researchers found that vivax patients had a significant and up-regulated 
TNFa and IL-6 levels and down-regulated of IL-1 a in patients before the start of 
treatment (Sohail et al., 2007). 
Temperature change is one of the responses to the biological active 
component of TNF. On the patients response to the differentiated level of TNF may 
reflect variation in their ability to neutralize and/or inactivate TNF. Nevertheless, 
production of cytokines in circulation is considered to be important because 
cytokines including TNFa are large hydrophilic peptides that would cross the blood 
brain barrier (BBB) in order to act on the hypothalamic thermoregulatory region that 
lead to the development of fever (Netea et al., 2000). Moreover, IL-6 contributes to 
the systemic action that stimulates the synthesis of acute phase proteins by 
hepatocytes (Abbas and Lichtman, 2005; Zetterstrom et al., 1998). These acute phase 
proteins act cohesively with TNF and IL-l to promote fever that- enhances the 
production of IL-6 during malaria infection (Zetterstrom et al., 1998). The 
importance of pyrogenic cytokines such as TNF, IL-l ~ and IL-6 in sustaining fever 
in malaria has also been demonstrated (Clark and Cowden, 2003). Furthermore, 
therapeutic trials of monoclonal anti-TNF antibodies have shown to abrogated febrile 
responses (Kwiatkowski et al., 1993). 
1.4.2 Anaemia 
Severe anaemia in non immune patient with an acute P. Jalciparum infection 
IS common and associated with haematological changes related to parasitaemia 
(Weatherall, 1988). Haematological changes of RBCs are the principal clinical 
outcome of malaria infection. All other clinical manifestations are primarily due to 
the involvement of RBCs. Anaemia is an important cause of morbidity and 
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potentially leads to mortality. Other clinical manifestation was reported to have less 
serious health consequences (Weatherall, 1988). 
Anaemia is an inevitable consequence of erythrocyte parasitization as all 
PRBCs are destroyed at merogony (schizont rupture). Furthermore, 
dyserythropoiesis enhanced splenic clearance and even blood loss that contributed 
towards malaria anaemia. The survival of non-parasitized erythrocytes was found 
reduced for several weeks after clearance of paras it aemi a in patients withJalciparum ' 
and vivax malarial (WHO, 2000). 
The merozoites of P. Jalciparum could infect a high proportion of RBCs 
leading to parasitaemia that resulted in >50 % of lethality. The mechanisms of 
anaemia are multifactor. The principle factors are haemolysis of parasitized red cells 
due to rupture of the schizonts; decline in the production of erythrocytes due to 
depression of erythropoiesis; increased phagocytosis of the red cells due to the 
change in sodium metabolisms; and haemo1ysis of the parasitized or unparasitized 
red cells through immunologic mechanism (Perin et aI., 1982). 
1.4.3 Thrombocytopenia 
Thrombocytopenia often occurs in most patients with Jalciparum and vivax 
malaria. Platelet survival is reduced to 2-4 days in severe Jalciparum malaria (WHO, 
2000). Thrombocytopenia may be related to the sequestration of the platelets in the 
spleen and disseminated intravascular coagulation (DIC). Platelets may be removed 
from the circulation at sites of fibrin deposition (Warrell et al., 2002). 
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1.4.4 Leucopenia 
In mild leucopenia, a neutrophil leucocytosis is detected in patient with 
severe falciparum malaria. Indeed, the severity of malaria correlates with the level of 
TNFa. (Day et al., 1999), neutrophil activation (Chen et al., 2000) and haemozoin 
loaded in circulating monocytes and neutrophils (de Souza and Riley, 2002). TNFa. 
is a major mediator of the acute inflammatory response that induces cellular 
functions in leukocytes leading to leukocytosis. This cytokine is important in 
reducing parasitaemia at its early production (Kremsner et al., 1995). However, the 
over expression of TNFa. could increase the severity of the disease (Day et al., 
1999). The excess of TNFa. production is also important in activation of endothelial 
cell expression of ligands for adhesion molecules which result in the subsequent 
sequestration of infected erythrocyte~, leukocytes and platelets thus le~ding to 
microvascular obstruction (Kremsner et al., 1995). 
1.5 Organ dysfunction in malaria 
Malaria infection in human causes dysfunction of multi organ (Warrell, 2002), 
such as brain, spleen, liver, lung, kidney and gastrointestinal organs. 
1.5.1 Brain 
The pathological changes of the blood brain barrier (BBB) leads to human 
cerebral malaria (Carvalho et al., 2000). Cerebral malaria (CM) is one of the most 
serious complications of falciparum infection, associated with neuropathological 
features causing a blockade of brain microvessels due to accumulation of host cells. 
Predominantly, erythrocytes are invaded by the parasite followed by sequestration of 
leukocytes and platelets as a result from adhesion of PRBC to receptor on the 
endothelial surface of the microvasculature (Potter et al., 2006; Combes et al., 2006). 
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These events could cause brain oedema, alterations of the BBB, microhaemorrhages 
and necrosis of the surrounding tissue (Coltel et al., 2004). On the post-mortem, 
specimen commonly reveals brain damage as the main factor of fatal syndrome 
(Combes et al., 2006). 
1.5.2 Spleen 
Splenomegaly is common in all four species of human malaria (Warrell et al., . 
2002). It is a well-established phenomenon in malaria endemic areas (Strickland et 
al., 1988; Greenwood et al., 1987; Bryceson et al., 1983; Thomas et al., 1981). In 
acute Jalciparum infections, the spleen is enlarged with either texture soft or firm, the 
colour varying from dark red to dark or state grey, depending on the duration of the 
infection and the amount of pigment (Warrell et al., 2002). Enlargement of the 
spleen may be detected a few days after the acute attack for non-immune or semi-
immune individuals, which then gradually decrease after recovery (Bryceson et al., 
1983). A huge splenomegaly with size >10 cm and high serum Immunoglobulin M 
(lgM) levels was reported in patients with hyperactive malaria splenomegaly 
(Fakunle, 1981). 
In vivax malaria, enlargement of the spleen is more rapid and might lead to 
splenic rupture. Splenic cords and sinuses are massively congested with monocytes 
and macrophages which contain pigment, PRBCs and non infected red cells. The red 
pulp is expanded and filled with lymphocytes, immunoblast and plasma cells. In 
addition, extramedullary haemopoiesis is a common phenomenon. Moreover, focal 
haemorrhage and infarction are also often observed. The process where pigment 
malaria mi!,;rate through the splenic cords, littoral cells phagocytose pigment as well 
as extract the malaria parasites from PRBCs is known as pitting. In patient with 
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repeated attacks of malaria, lymphoid compartment of white pulp exhibits a 
considerable depletion. However, the red pulp still exhibits reticuloendothelial 
hyperplasia with thickening of the fibrous trabulae and capsule (Warrell et al., 2002). 
1.5.3 Liver 
It is known that plasmodia infection causes hepatomegaly (von Brand, 1973) 
but the condition tends to be more severe in P. Jalciparum infection. The major' 
changes are in the hepatic sinusoids and lining cells with relatively little damage to 
hepatocytes. After the first paroxysms, the usual circumstances are enlarged liver, 
sequestered blood cells and sinusoidal engorgement. The liver is oedematous and its 
colour is either brown, grey or even black as a result of deposition of malaria 
pigment. In acute infection with repeated attacks on lobular accentuation will cause 
the accumulation of the pigment in the portal tracts, the liver possibly friable and 
firm. 
Intrahepatocyte schizonts and merozoites were observed without 
inflammatory changes. In early infection, hepatic sinusoids are dilated due to 
congestion with Kupffer cell hyperplasia, PRBCs and fine pigment in red cells and 
Kupffer cells. The increase number of Kupffer cells, endothelial cells and sinusoidal 
macrophages that were recruited by the spleen led to phagocytosis on PRBCs and 
non infected erythrocyte. The filling of infected erythrocytes in the sinusoids causes 
the reduction of hepatic circulation which lead to splanchnic constriction (Warrell et 
at., 2002). Severe liver failure is the other common clinical complication of untreated 
cases (Ramasamy, 1998). 
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1.5.4 Lungs 
Certain complications are reported on lungs in malaria infection. Pneumonia 
is one of fatal complication of severe Jalciparum malaria (Warrell et ai., 2002). 
Besides, respiratory complications due to severe malaria are frequent phenomena, 
although it is increasingly recognized that tachypnoea and abnormal breathing 
patterns are often related to respiratory acidosis that may indicate generalized 
metabolic abnormalities or intracranial events rather than primary lung disease' 
(Crawley et ai., 1998). 
Malaria infection can cause pulmonary oedema that is identified commonly 
by both free alveolar fluid and interstitial oedema. Morphologically, the infected lung 
is dark with scattered haemorrhages. Numerous alveolar and septal haemorrhages 
may present due to accumulation of leukocytes in alveolar vessels. The alveoli are 
usually found congested with pigment-laden macrophages, plasma cells, neutrophils 
and PRBCs. Leukocytes are seen adherent to alveolar endothelial cells. Activated 
macrophages and lymphocytes occur in acute pulmonary syndrome (Warrell et ai., 
2002). Acute pulmonary oedema is an infrequent but nearly fatal complication in 
untreated cases of acute Jaiciparum malaria (Ramasamy, 1998). 
1.5.5 Kidney 
In severe Jaiciparum, renal dysfunction is commpn in non-immune adult 
indicated by proteinuria (Fletcher and Gilles, 1988). The acute renal failure may 
develop, associated with anuria and acidosis as part of multisystem ilhiess that 
induce haemodynamic shock and jaundice. On the acute tubular necrosis, PRBCs, 
host leukocytes and pigment-laden macrophages are found within glomerular 
capillaries and interstitial vessels. It has been reported that the density of parasite 
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sequestration in kidney is often less compared to other organs, despite its remarkable 
content of lymphocyte, besides, fibrin thrombi can be seen in some glomerular 
capillaries and tubular red cells casts are also observed (Warrell et at., 2002). In 
P. malariae infection, nephrotic syndrome oedema appears to be common (Quartan 
malaria nephropathy) (Playfair and Bancroft, 2004). In acute Jalciparum malaria, 
glomerulonephritis is also a common phenomenon and usually associated with 
proteinuria, with or without haematuria. The glomeruli become hypercellular with ' 
expansion of mesangial ground substance, noticeably thickened glomerular on 
membranes base, swollen glomeruli and obvious adhesions to Bowman's capsule 
(Warrell et al., 2002). 
The passage of dark or red urine in malaria, known as black water fever 
(BWF) is linked to renal failure that is attributed to acute haemoglobinuria and 
intravascular haemolysis (WHO, 1990). The syndrome is generally seen in people 
with limited immunity to malaria (Bruneel et al., 2001). Recently, dark urine 
attributed to myoglobinuria in adult who had complicated by rhabdomyolysis was 
reported (Sinniah and Lye, 2000; De Silva et ai., 1988). The occurrence of dark urine 
in children with malaria is frequent. Both haemoglobin and myoglobin are said to 
contribute to dark urine in children with malaria. Muscle cell injury that also 
contributes to dark urine is more common in children with intravascular haemolysis 
(Donnel et al., 2006). 
1.5.6 Gastrointestinal organs 
Gastrointestinal symptoms such as anorexia, nausea, vomiting and abdominal 
pam are usually associated with acute Jalciparum malaria. Sequestration and 
cytoadherence occur in small and large bowel, predominantly within the lamina 
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propriety capillaries and also in larger submucosal vessels. In many severe cases, 
mucosal ulceration and haemorrhage may develop. At this stage, fibrin thrombi can 
be found in small blood vessels (Warrell et al., 2002). 
In the severest form of malaria, diarrhea may develop. Fatal gastrointestinal 
bleeding has been reported with high P. Jalciparum parasitaemia (Boonpucknavig et 
at., 1984). Multiple foci of mucosal haemorrhage were observed in stomach and 
small intestine (except jejunum) but less prominent in colon. Gastrointestinal 
dysfunction is identified by some changes of absorptive function. Apart from 
congestion and pigmentation as a result of high parasitaemia,. the pancreas 
demonstrates some alteration of vascular congestion with parasitized and non-
parasitized erythrocytes and the presence of pigment-laden macrophages. There are 
generally no major pathological alterations of the gastrointestinal tract in vivax and 
quartan malaria (Fletcher and Gilles, 1988). 
1.6 Immunity to malaria 
Immunity is a reaction of the body towards foreign substances, i.e. 
macromolecules such as proteins and polysaccharides. The immune system can be 
induced by cells and molecules (Abbas and Lichtman, 2005). It physiologically 
functions to fight against infection (Abbas and Lichtman, 2005; Bruce-Chwatt, 
1985). 
The role of the spleen in the immune response has been known. A study 
shows that removal of this organ affects profoundly the course of malaria in animal 
or human subjects where protection is seen with intact spleen when challenged with 
the asexual intra-erythrocytic forms of the parasite (Bruce-Chwatt, 1985). 
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1.6.1 Innate immunity 
Innate imIimnity is also called natural or native immunity, it acts as an early 
line of defense against the infection. It also stimulates and modulate adaptive 
immune responses (Abbas and Lichtman, 2005; Carayannopoulos and Yokoyama, 
2004). Innate immunity consists of cellular and biochemical defense mechanism 
prior to infection and poised to respond rapidly towards infections. The principal 
components to innate immunity involve physical and chemical barriers, such as' 
production of epithelia and antimicrobial substances produced at epithelial surfaces. 
The component of innate immunity include phagocytic cells, (neutrophils, 
macrophages) and natural killer (NK) cells, blood proteins, including members of the 
complement system, mediators of inflammation and proteins called cytokines that 
regulate and coordinate many of the activities of the cells (Abbas and Lichtman, 
2005). 
Innate Immune system contributes to the control of acute infection by 
mounting protective responses against invading pathogens before the onset of T and 
B cell-mediated immunity. NK cells are known to be the key players in these early 
innate responses (Carayannopoulos and Yokoyama, 2004). The role of NK cells in 
immunity to malaria is investigated by administrating exogenous IL-12 in susceptible 
NJ mice infected with P. chabaudi chabaudi AS parasite. The result shows that the 
mice exhibit the NK cell related mechanism of immunity in early stages of the 
disease. The result significantly indicates that at the initial stage of infection, 
interferon-y (IFNy), TNFa and nitric oxide (NO) were detected (Stevenson et al., 
2001). 
NK cells are large, granular, cytotoxic lymphocytes that can recognize and 
destroy aberrant cells such as those infected by intracellular viral, bacterial, protozoa 
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pathogens, transfonned cells and a range of stress induced molecules (Hansen et al., 
2007; Robbin and Brossay, 2002). NK cells can also be rapidly activated to produce 
high levels of pro-inflammatory cytokines, particularly IFNy, TNFa, lymphotoxin-a 
(LTa), granulocytes-macrophage colony stimulating factor (GM-CSF), IL-3 and 
tumour growth factor-~ (TGF-~) (Hansen et al., 2007; Robertson, 2002). NK Cells 
are able to influence adaptive immunity by modulating dendritic cell (DC) function 
and inducing the T helper type 1 (Thl) polarization via IFNy production (Hansen et 
al., 2007). The invasion of pathogens, or antigens of viral, bacterial and protozoa, are 
captured by dendritic cells (DCs) or monocyte macrophages which then release NK 
cell-activating cytokines (Cooper et al., 2004; Ferlazzo et al., 2003; Lande et a/., 
2003; Sher et al., 2003; Biron et al., 1999). 
Interleukin-2, IL-12, IL-15, IL-18, TNFa, and IFNa/~ all contribute to 
activation of NK cells whereas IL-4, IL-lO and TGF-~ suppress NK cells function 
(Colucci et al., 2003; Biron et al., 1999). Interleukin-12 is a pro-inflammatory 
cytokine mainly produced by macrophages and Des is the most potent inducer of 
NK cell cytotoxicity and IFNy secretion, along with IL-18, it plays a crucial role in 
triggering NK -mediated immune responses (Wei et al., 1999; Trinchieri, 1998). NK 
cells appear to play an important role in the early immune response to a wide variety 
of pathogens, including a number of protozoal infections (Korbel et al., 2004). 
The principal innate immune response to protozoa IS phagocytosis, but many 
of these parasites are resistant to phagocytic killing and may even replicate within 
macrophages. Parasites recovered from infected hosts appear to develop resistance to 
complement-mediated lysis (Abbas and Lichtman, 2005). 
Macrophage function is reduced in malaria infection (Nielsen et al., 1986). It 
has shown that inhibition of macrophage function is due to granules of malaria 
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pigment known as haemozoin. The haemozoin pigments consist of insoluble 
polymers resulting from the ingestion of intraerythrocytic malaria parasites that are 
unable to catabolise haem that precipitates in the erythrocytes. However, the 
accumulation of pigment inside macrophages has been shown to impair macrophage 
activation and function (Malaguamera and Musumeci, 2002a). Haemozoin is a key 
factor in malaria-associated immunosuppression; affecting both the antigen 
processing and immunomodulatory function of macro phages (Metzger et al., 1995). 
Macrophages phagocytose the PRBCs, it is intriguing that macrophages may 
not only ingest intact infected erythrocytes but also extract parasites from recently 
infected erythrocytes, leaving the erythrocytes to continue to circulate (Chotivanich 
et al., 2002; Angus et al., 1997). Macrophage participates in the control of the 
infection through both antibody dependent and independent phagocytosis, and also 
through the secretion of soluble factors directly or indirectly toxic to the parasite, 
such as IL-1, TNFa, GM-CSF, reactive nitrogen (NOI) and oxygen radicals (ROI) 
(Prada et aI., 1996). 
1.6.2 Adaptive immunity 
Adaptive immunity is immune responses that are stimulated resulting from 
exposure to infectious agents, it was then developed as a response to infection and 
also adaption to the infection (Abbas and Lichtman, 2005).,Acquisition of protection 
following natural parasite exposure is a slow process that may take years or decades 
to develop and probably never results in sterile immunity (Greenwood, 2005). There 
are two types of adaptive immune responses, namely humoral immunity and cell-
mediated immunity. These two immune responses are mediated by different 
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components of antigen, both the immune systems function to eliminate different 
types of infection (Abbas and Lichtman, 2005). 
1.6.2.1 Humoral immunity 
Humoral immunity is mediated by molecules in the blood and mucosal 
secretions, called antibodies, which is produced by B lymphocytes cells (also called 
B cells). Antibodies recognize parasite antigens and consequently neutralize the' 
infectivity of the parasite. The principal defense mechanism in humoral immunity is 
against intracellular microbes and their toxins by binding onto these microbes and 
toxins for their elimination (Abbas and Lichtman, 2005). 
1.6.2.2 Cell-mediated immunity 
Cell-mediated immunity, also called cellular immunity is mediated by T 
lymphocytes or also known as T cells. Intracellular parasites survive and proliferate 
inside phagocytes and other host cells, where they are inaccessible to circulating 
antibodies. The function of cell-mediated immunity is as defensive systems against 
infections, particularly macrophage activation by Th1 cell-derived cytokines which 
promotes the destruction of parasites residing in phagocytes. It also kills the infected 
cells and eliminates the reservoirs of infection. 
Protective immunity against protozoa may be induced by the host's response 
through production of antibodies or lymphocytes specific for the parasite. Protective 
immunity to the asexual blood forms of malaria parasites is mediated by mechanism 
that involves both cellular and antibody (Abbas and Lichtman, 2005). 
Multiple genes appear to control and protect against intracellular parasites in 
mice and presumably in humans. Attempts to identify these genes are ongoing in 
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many laboratories. Protozoa that replicate inside various host cells lyse were found to 
stimulate both specific antibody and cytotoxic T lymphocytes (CTL) responses. It 
was thought for many years that antibodies were the major protective mechanism 
against malaria as the vaccination against this infection was focused on generating 
antibodies. It is now apparent that the CTL response is an important defense 
mechanism against the spread of this intracellular protozoan (Abbas and Lichtman, 
2005). 
The three immunoglobulins: IgG, IgM and 19A have shown to exert various 
degree of specific activity against malaria. Studies conducted in. non-immune 
volunteers showed that serum concentration of IgG, IgM and 19A rose shortly after 
beginning of parasitaemia. The levels of IgG, IgM were higher than 19A, while IgG 
persisted longer than the other two (Bruce-Chwatt, i 985). 
The T cell could either act by promoting cell-mediated immunity against the 
parasite or to producing specific antibody as demonstrated by murine models (Fell 
and Smith, 1998). Thl type T cell was confirmed to be responsible for controlling 
the primary acute parasitaemia as demonstrated in the model of malaria immunity in 
mice infected with P. chabaudi (Langhorne et ai., 1995). The·responses ofT cells are 
expected to inhibit the parasite growth by: (1) phagocytosis of granulocytes and 
macrophages through the production of cytokines such as IL-12 and TNF by 
macrophages in response to parasite molecules that lead to macrophage activation, 
increased phagocytosis and production of oxygen radicals and NO; (2) Activation of 
yo T cells; and (3) activation of NK cells and the production of IFNy by these cells 
(Biron and Gazzinelli, 1995). 
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1.6.3 Passive Immunity 
Immunity can also be conferred on an individual by transferring serum or 
lymphocytes from a specifically immunized individual. This type of immunity is also 
known as adoptive transfer. The recipient of such a transfer becomes immune to the 
particular antigen without being exposed or having responded to antigen. Therefore, 
this form of immunity is called passive immunity. Passive immunization is a useful 
method for distributing immunity rapidly without having to wait for an active' 
immune response to develop. It is a similar mechanism as transferring of maternal 
antibodies to the fetus to enable the newborns to combat infections in~tant1y (Abbas 
and Lichtman, 2005). 
In P. Jalciparum infection, the immune mechanism is largely mediated by 
immunoglobulin G (IgG) (Sabchareon et al., 1991), the role for the antibody was 
demonstrated by the passive transfer of adult immune IgG to infected children 
(McGregor, 1964b). 
1.6.4 Age and malaria 
Age was reported to influence the acquisition of immunity (Marsh, 1993). For 
example, newborns receive passive immunity from their mother, they usually have 
lower chances to contact parasitaemia and even during intensive transmission and 
therefore children less than 6 months rarely show clinical features of severe malaria 
(Snow et al., 1997). However, they become highly susceptible thereafter (Bruce-
Chwatt, 1985) when the level of antibodies declined and thus the ability to develop 
the effective acquired anti-parasite immunity dropped (Marsh, 1993). Due to this 
reason, children aged 3-5 often harbour high parasite loads and are the more 
susceptible group to P. Jalciparum. A significant proportion of these children died 
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from cerebral malaria and other severe complications (Taylor-Robinson, 2002). 
Older children exposed continuously to the parasite for many years will tend to 
accumulate an active acquired immune response that is sufficient to lessen the 
parasite rate and severity of the symptoms. In adulthood, clinical attacks are 
generally self-limiting fevers and headache, and parasitaemia initially stabilizes at a 
low level but later develops into serious symptoms particularly those from the non 
endemic areas. Acquired immunity in adults exposed to a long unbroken period of ' 
heavy exposure, is neither sterile nor permanent. In comparison semi-immune 
individuals often appear healthy despite harbouring parasites. Persist~nt immunity 
requires years to develop. The maintenance of this persistent immunity known as 
premunition depends upon a persistent subclinical infection and is lost when an 
individual leaves the malaria-endemic area (Taylor-Robinson, 1998). 
Unlike other acute viral diseases which produce life long resistance to 
reinfection, malaria only elicits immunity after several years of continuous exposure, 
during the period of recurring infections, illness occurs. This tum of malaria 
immunity is only partially effective and results in milder or sometimes asymptomatic 
infections when harbouring low blood-borne parasitaemias. This immunity is short-
lived unless it is reinforced through frequent reinfection and is therefore only 
acquired or semi-immune adults resident in malaria endemic areas (WHO, 1996). 
1.6.5 Malaria in pregnancy 
The risk of infection is highest for women when conceived a baby for the first 
time (primigravidae) and the risk is reduced, although not absent, in subsequent 
pregnancy, indicating the development of effective immune responses to these 
infections. Two host factors are responsible for the increased susceptibility to malaria 
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III pregnant women (Rogerson and Beeson, 1999; Menendez, 1995) which are 
changes in immunological responses that could reduce the parasite clearance (Lea 
and Cadler, 1997; Riley et at., 1989) and changes in specific antimalarial antibodies 
(Nambei et aI., 1998; Deloron et at., 1989). The immune mechanism during 
pregnancy down-regulates inflammatory type Thl responses and shifts to a 
predominant Th2 response that contributes to the increased susceptibility of pregnant 
women towards infection. This may lead to increased morbidity and mortality' 
(Taylor-Robinson, 2002; Krishnan et at., 1996; Wegmann et at., 1993). Studies 
conducted in pregnant mice with malaria showed that since Thl mediation that is 
instrumental in controlling acute infection was down-regulated, switching to Th2 
resulted in increased pathogenicity of the disease (Krishnan et at., 1996; Wegmann et 
aI., 1993). 
1.7 Rodent models of malaria 
Host specificity demonstrated by human malaria parasites is the major 
constraint for the study of malaria. Furthermore, the actual causative organisms 
cannot be maintained in the small laboratory animals. In early 1950s, simian and 
avian parasites were the only models available until the surfacing of P. berghei, 
which is now used in many laboratories internationally (Cox, 1988). 
In in vivo protective immunity studies, various models systems have been 
developed using parasites isolated from thicket rats in five different countries of 
Aftica (Carlton et ai., 2001; Taylor-Robinson, 1998). These parasites have shown to 
be better than simian and avian malaria models in that they are easy and cheaper to 
maintain. Mouse immune system is well characterized, where large-scale of 
dissection can be performed that is impossible to be carried out in humans or non-
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human primates (Taylor-Robinson, 1998). Four species of rodent malaria, P. berghei, 
P. yoelii, P. chabaudi, and P. vinckei have been adapted to be grown in the 
laboratory (Killick-Kendrick and Peters, 1978; Carter and Diggs, 1977). 
Plasmodium berghei and P. yoelii, like P. vivax and P. ovale, are able to 
invade reticulocytes, whereas P. chabaudi and P. vinckei preferentially invade 
mature red blood cells, as do P.Jalciparum and P. malariae (Cox, 1988). Like 
P. Jalciparum, rodent malaria parasites have 14 chromosomes, which are' 
polymorphic both between species and between isolates of the same species (Carlton 
et al., 2001). P. berghei and P. vinckei vinckei, and some of P. chabaud~ and P. yoelii 
strains cause lethal infection in mice, whereas P. chabaudi adami, P. chabaudi 
chabaudi, P. vinckei petteri and other isolates of P. yoelii cause infections in most 
strains of mice which resolve after the initial parasitaemia is then either eliminated 
completely (P. yoelii) or have smaller patent recrudescence for several months 
(P. chabaudi chabaudi, P. vinckei petteri) (Cox, 1988). Lethal infections are 
preferably used for screening of compounds with chemotherapeutic activity (Taylor-
Robinson, 1995), testing of putative vaccine candidate molecules and examining of 
vaccine-induced immunity. Non-lethal infections serve well as models to investigate 
the mechanisms of acquired immunity (Taylor-Robinson, 1998). 
The model parasites most commonly used are the sibling species P. berghei 
and P. yoelii, which share more than 90% genome identity (Kooij et aI., 2005). Both 
present numerous similarities to human P. Jalciparum and P. vivax and are 
extensively used to study the biological changes of liver stage and blood stage 
antigens and their role in immunity and vaccine development (Carlton et ai., 2005). 
In recent years, numerous studies have used P. berghei to understand Plasmodium 
infection of liver, blood and mosquito (Franke-Fayard et al., 2005; Frevert et al., 
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